The role of anti‐müllerian hormone as a predictor of ovarian function

Abstract

Key content Levels of anti‐müllerian hormone (AMH), which is secreted by the granulosa cells of the ovary, indicate the size of the antral follicle pool. Along with other predictors, AMH levels can predict the quantitative response to treatment in women undergoing assisted reproductive therapy. The aim of AMH testing in assisted reproductive therapy is mainly to individualise treatment protocols with a view to achieving the optimal ovarian response and oocyte yield. AMH has not shown sufficient predictive value for pregnancy outcome to be used in routine practice for either spontaneous pregnancy or following assisted reproductive therapy. AMH serves a diagnostic and prognostic role in the management of women with polycystic ovary syndrome. Learning objectives To understand the physiology of AMH and its role in reproductive function. To identify the role of AMH as a predictor of fertility and ovarian reserve. To understand the role of AMH in assisted reproductive therapy. Ethical issues Is it ethical to make decisions about refusing treatment based on AMH levels? Can women be reassured that they can delay childbearing on the basis of their AMH levels?